Geriatric Assessment to support older patients undergoing allo-HSCT

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects patient, disease, donor, and treatment information to identify risk factors that influence transplant outcomes in elderly patients. It aims to build a comprehensive geriatric assessment model and use it to guide personalized pre-transplant strategies. The analysis considers age, physical function, comorbidities, disease characteristics, donor details, conditioning regimens, graft source, and GVHD prophylaxis. The goal is to reduce transplant-related mortality and improve overall allo-HSCT outcomes in the elderly population. The study is led by Peking University People’s Hospital in Beijing and does not list collaborators.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* (a)Age ≥55 years.
* (b)Hematologic disorders with established indications for transplantation, including malignant and non-malignant hematologic diseases. (c)Willingness to provide informed consent.

Exclusion Criteria: (a)Pregnancy. (b) Uncontrolled active infection. (c) Lack of informed consent. (d)Deemed ineligible for transplantation after investigator assessment

Where it's running

• Peking University People's Hospital
  Beijing, China Recruiting

Study contacts

• Study coordinator: Yuqian Sun
• Email: sunyuqian83@hotmail.com
• Phone: 861088326666

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term心理 and cognitive check after stem cell transplant for immune deficiencies

  This study tests the long-term neurocognitive and psychological functioning of 6–8 year-old children who had an allogeneic stem cell transplant for a primary immune deficiency, at least two years after the transplant.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07766304

• Low-dose Liposomal Amphotericin B for preventing fungal infections in adults with blood cancers and prolonged neutropenia

  This study tests whether giving a daily 50 mg dose of liposomal amphotericin B can help prevent invasive fungal infections in adults with blood cancers who have prolonged low white blood cell counts.

  Recruiting Haikou Affiliated Hospital of Central South University Xiangya School of Medicine · Hainan, Hainan · NCT07763054

• Moxibustion with second-line treatment for steroid-refractory acute graft-versus-host disease after transplant

  This study will test whether adding moxibustion to standard second-line drug therapy helps people aged 14–65 with steroid-refractory gastrointestinal acute GVHD after an allogeneic stem cell transplant.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07572669

• Baricitinib for persistent low platelets after stem cell transplant

  We’re testing baricitinib to see if it can help people with long-term low platelets after an allogeneic stem cell transplant who didn’t respond to other treatments.

  Recruiting Phase 1/2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT07535645

• Adding venetoclax to fludarabine–melphalan conditioning for people over 50 with AML or MDS getting a donor stem cell transplant

  This tests whether adding venetoclax to standard fludarabine–melphalan conditioning helps people over 50 with AML or MDS who are having an allogeneic stem cell transplant.

  Recruiting at 18 sites Phase 3 First Affiliated Hospital of Zhejiang University · Fuzhou, Fujian and 17 other locations · NCT07396480

• Adjuvant CDK4/6 Inhibitors in Older Breast Cancer Patients: Geriatric Screening in Action

  This study tests whether using geriatric screening alongside adjuvant CDK4/6 inhibitors helps tailor therapy for adults aged 70 and older with early-stage breast cancer.

  Recruiting at 4 sites Region Jönköping County · Gävle and 4 other locations · NCT07273357

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.